31-Jul-2026
Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026
Globe Newswire (Wed, 29-Jul 8:30 AM ET)
Market Chameleon (Thu, 11-Jun 4:44 AM ET)
Globe Newswire (Thu, 11-Jun 8:30 AM ET)
Liquidia Corporation Announces Inclusion in the S&P SmallCap 600 Index
Globe Newswire (Mon, 8-Jun 8:30 AM ET)
Liquidia’s Inclusion in S&P SmallCap 600 Highlights Growing Momentum in Healthcare Sector
Market Chameleon (Mon, 8-Jun 3:31 AM ET)
Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
PRNewswire (Fri, 5-Jun 7:26 PM ET)
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
Globe Newswire (Wed, 27-May 8:30 AM ET)
Market Chameleon (Mon, 11-May 7:07 AM ET)
Liquidia Corporation Reports First Quarter 2026 Financial Results
Globe Newswire (Mon, 11-May 6:30 AM ET)
Liquidia Corporation to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 6-May 8:30 AM ET)
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Liquidia trades on the NASDAQ stock market under the symbol LQDA.
As of July 31, 2026, LQDA stock price declined to $84.11 with 1,081,456 million shares trading.
LQDA has a beta of 0.31, meaning it tends to be less sensitive to market movements. LQDA has a correlation of 0.00 to the broad based SPY ETF.
LQDA has a market cap of $7.48 billion. This is considered a Mid Cap stock.
Last quarter Liquidia reported $133 million in Revenue and $.52 earnings per share. This beat revenue expectation by $16 million and exceeded earnings estimates by $.13.
In the last 3 years, LQDA traded as high as $91.10 and as low as $5.71.
The top ETF exchange traded funds that LQDA belongs to (by Net Assets): IJR, VTI, IWM, VXF, SPSM.
LQDA has outperformed the market in the last year with a price return of +350.0% while the SPY ETF gained +19.4%. LQDA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +114.5% and +5.2%, respectively, while the SPY returned +4.2% and +0.5%, respectively.
LQDA support price is $82.90 and resistance is $90.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LQDA shares will trade within this expected range on the day.